Cantor Fitzgerald Forecasts CRVS FY2025 Earnings

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) – Stock analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for Corvus Pharmaceuticals in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst L. Watsek anticipates that the company will post earnings of ($0.46) per share for the year. The consensus estimate for Corvus Pharmaceuticals’ current full-year earnings is ($0.63) per share.

Several other equities research analysts have also recently weighed in on CRVS. HC Wainwright restated a “buy” rating and set a $11.00 target price on shares of Corvus Pharmaceuticals in a research note on Tuesday, January 14th. Oppenheimer upped their target price on shares of Corvus Pharmaceuticals from $8.00 to $14.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. Mizuho upgraded shares of Corvus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 22nd. Finally, StockNews.com cut shares of Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, four have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $12.38.

Corvus Pharmaceuticals Price Performance

Corvus Pharmaceuticals stock opened at $5.22 on Wednesday. The stock’s fifty day moving average is $6.86 and its two-hundred day moving average is $5.61. The stock has a market cap of $335.44 million, a PE ratio of -5.61 and a beta of 1.07. Corvus Pharmaceuticals has a 1-year low of $1.30 and a 1-year high of $10.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Samlyn Capital LLC lifted its holdings in shares of Corvus Pharmaceuticals by 160.7% during the second quarter. Samlyn Capital LLC now owns 6,123,021 shares of the company’s stock worth $11,144,000 after purchasing an additional 3,774,658 shares during the period. Point72 Asset Management L.P. purchased a new position in Corvus Pharmaceuticals in the second quarter valued at about $10,855,000. Geode Capital Management LLC boosted its stake in shares of Corvus Pharmaceuticals by 22.4% during the 3rd quarter. Geode Capital Management LLC now owns 563,009 shares of the company’s stock worth $2,974,000 after acquiring an additional 102,869 shares in the last quarter. Jane Street Group LLC purchased a new position in Corvus Pharmaceuticals in the 3rd quarter valued at approximately $265,000. Finally, Connor Clark & Lunn Investment Management Ltd. raised its holdings in Corvus Pharmaceuticals by 64.7% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 137,031 shares of the company’s stock worth $724,000 after purchasing an additional 53,809 shares during the last quarter. 46.64% of the stock is owned by hedge funds and other institutional investors.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.